Company Announcement no. 24/2013

To: NASDAQ OMX Copenhagen A/S                                               Hørsholm, Denmark, 17 December 2013

Veloxis Pharmaceuticals Announces Financial Calendar for 2014

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for 2014.

5. March, 2014:                     Release of Annual Report 2013.

9 April, 2014:                        Annual General Meeting.

14 May, 2014:                       Interim Report for the 1st Quarter ‐ for the period 1 January to 31 March, 2014.

20 August, 2014:                   Interim Report for the 2nd Quarter – for the period 1 January to 30 June, 2014.

12 November, 2014:              Interim Report for the 3rd Quarter – for the period 1 January to 30 September, 2014.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino                                                  Johnny Stilou

President & CEO                                          EVP, Chief Financial Officer

Mobile: +1 917 647 9107                              Mobile: +45 21 227 227

Email: wjp@veloxis.com                               Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc.

Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.